As of 2025-03-17, the EV/EBITDA ratio of Altimmune Inc (ALT) is -4.07. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Altimmune's latest enterprise value is 418.97 mil USD. Altimmune's TTM EBITDA according to its financial statements is -102.89 mil USD. Dividing these 2 quantities gives us the above Altimmune EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.8x - 12.2x | 10.5x |
| Forward P/E multiples | 21.6x - 24.4x | 23.0x |
| Fair Price | (28.38) - (15.82) | (21.90) |
| Upside | -579.4% - -367.2% | -469.9% |
| Date | EV/EBITDA |
| 2025-03-17 | -3.92 |
| 2025-03-14 | -4.07 |
| 2025-03-13 | -3.53 |
| 2025-03-12 | -3.80 |
| 2025-03-11 | -3.58 |
| 2025-03-10 | -3.72 |
| 2025-03-07 | -3.81 |
| 2025-03-06 | -3.83 |
| 2025-03-05 | -3.92 |
| 2025-03-04 | -4.10 |
| 2025-03-03 | -4.12 |
| 2025-02-28 | -4.62 |
| 2025-02-27 | -4.45 |
| 2025-02-26 | -4.09 |
| 2025-02-25 | -4.06 |
| 2025-02-24 | -4.21 |
| 2025-02-21 | -4.45 |
| 2025-02-20 | -4.60 |
| 2025-02-19 | -4.72 |
| 2025-02-18 | -4.49 |
| 2025-02-14 | -4.41 |
| 2025-02-13 | -4.30 |
| 2025-02-12 | -4.30 |
| 2025-02-11 | -4.35 |
| 2025-02-10 | -4.59 |
| 2025-02-07 | -4.63 |
| 2025-02-06 | -4.81 |
| 2025-02-05 | -4.87 |
| 2025-02-04 | -4.61 |
| 2025-02-03 | -4.46 |
| 2025-01-31 | -4.61 |
| 2025-01-30 | -4.88 |
| 2025-01-29 | -4.84 |
| 2025-01-28 | -4.83 |
| 2025-01-27 | -4.88 |
| 2025-01-24 | -4.87 |
| 2025-01-23 | -4.93 |
| 2025-01-22 | -4.84 |
| 2025-01-21 | -4.75 |
| 2025-01-17 | -4.78 |
| 2025-01-16 | -4.66 |
| 2025-01-15 | -4.57 |
| 2025-01-14 | -4.30 |
| 2025-01-13 | -4.72 |
| 2025-01-10 | -4.78 |
| 2025-01-08 | -5.22 |
| 2025-01-07 | -5.11 |
| 2025-01-06 | -5.07 |
| 2025-01-03 | -5.08 |
| 2025-01-02 | -4.96 |